Bristol-Myers Squibb Company





Market Closed - Nyse 04:00:02 2023-12-08 pm EST Intraday chart for Bristol-Myers Squibb Company 5-day change 1st Jan Change
50.31 USD +0.30% +0.42% -30.08%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Global markets live: AbbVie, McDonald's, Apple, AMD, Alphabet...
Are rate cuts are coming early next year?
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
S&P, Nasdaq eye higher open on Alphabet boost, payrolls data in focus RE
Bristol-Myers Squibb Adds $3 Billion to Buyback Program MT
Bristol-Myers Squibb Says Phase 3 Trial of Opdivo and Yervoy Achieved Primary Endpoint MT
Bristol Myers: share buyback program expanded CF
Bristol-Myers Squibb Company Announces Phase 3 Checkmate -8Hw Trial Evaluating Opdivo Plus Yervoy Compared to Chemotherapy in Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary CI
Bristol Myers Adds $3 Billion to Stock Buyback Program DJ
Bristol Myers: 5% dividend increase CF
Bristol-Myers Squibb Raises Quarterly Dividend to $0.60 a Share from $0.57, Payable on Feb. 1 to Shareholders as of Jan. 5 MT
Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents DJ
Bristol-Myers Squibb Company Declares Quarterly Dividend on Common Stock, Payable on February 1, 2024 CI
UniCredit seeks new chair candidate by early 2024, sources say RE
IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Diseases CI
UniCredit seeks new chair candidate by early 2024, sources say RE
Bristol-Myers Squibb Says Application for Bladder Cancer Combo Therapy Gets Priority Review Status From US FDA MT
Bristol Myers Gets FDA Priority Review of Opdivo-Chemotherapy Combo in Bladder Cancer DJ
Bristol Myers: priority review status granted for Opdivo CF
Bristol Myers Squibb Announces U.S. Food and Drug Administration Accept the Supplemental Biologics License Application for Opdivo CI
Blackstone explores sale of Anthos Therapeutics -sources RE
Blackstone explores sale of Anthos Therapeutics -sources RE
Bristol Myers Squibb Insider Bought Shares Worth $150,049, According to a Recent SEC Filing MT
US FDA investigating safety risk of CAR-T cancer therapies RE
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells DJ
Chart Bristol-Myers Squibb Company
More charts
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi.
-30.08% 102 B $
+63.47% 538 B $
+42.56% 430 B $
-12.58% 372 B $
-7.63% 264 B $
-6.49% 263 B $
-12.81% 232 B $
+1.35% 198 B $
-9.77% 197 B $
-43.83% 163 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Bristol-Myers Squibb Company - Nyse
  4. News Bristol-Myers Squibb Company
  5. Jefferies Trims Bristol-Myers Squibb's Price Target to $61 From $62, Hold Rating Maintained
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration